APEIRON Biologics’ APN01 selected for large-scale US trial in COVID-19

  • APEIRON ́s APN01 to participate in US Phase 2 COVID-19 trial ACTIV-4d RAAS
  • Further clinical study in preparation with inhalative drug delivery of APN01 to
    directly target respiratory tract and lung tissue
  • Additional pre-clinical data show highly promising results with APN01 in various
    mutation variants
  • Financing round planned to secure funding of further upcoming development steps

Press release (EN) | Presseaussendung (DE)